Early Phase 1
N=9
Gynecological Sentinel Lymph Nodes CEUS
Cervical Carcinoma · Malignant Female Reproductive System Neoplasm · Vaginal Carcinoma · Vulvar Carcinoma
Bottom Line
View on ClinicalTrials.gov: NCT05105087 ↗Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT) — 17 sentinel lymph nodes (SLNs)
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Perflubutane Microbubble (Drug); Contrast-Enhanced Ultrasound (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Thomas Jefferson University
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT) |
17 | — |
| SECONDARY Location of Sentinel Lymph Nodes (SLNs) Identified by Contrast-enhanced Ultrasound (CEUS) |
9; 7; 1 | — |
| SECONDARY Size of Sentinel Lymph Nodes (SLNs) Identified |
1.6 | — |
| SECONDARY Depth Beneath the Skin Surface of Each SLN |
2.71 | — |
| SECONDARY Presence of Metastatic Deposits in the Sentinel Lymph Node (SLNs) |
3 | — |
Summary
This clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes (SLNs) to the standard of care (which varies depending on cancer treatment). The ultrasound contrast agent is called Sonazoid and it consists of tiny gas-filled bubbles about the side of red blood cells. Diagnostic procedures, such as ultrasound with Sonazoid, may help identify more SLNs than standard of care in patients with cervical, vaginal, or vulvar cancer.
Eligibility Criteria
Inclusion Criteria
- Be female
- Be diagnosed with cervical, vaginal or vulvar cancer
- Be at least 18 years of age
- If of child-bearing potential, must have a negative pregnancy test
- Be able to comply with study procedures
- Have read and signed the Institutional Review Board (IRB)-approved informed consent form for participating in the study
Exclusion Criteria
- Females who are pregnant or nursing
- Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards
- Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:
- Patients on life support or in a critical care unit
- Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia
- Patients with recent cerebral hemorrhage
- Patients who have undergone surgery within 24 hours prior to the study sonographic examination
- Patients with congenital heart defects
- Patient with a known allergy to Sonazoid (including an anaphylactic allergy to eggs or egg products)
Data sourced from ClinicalTrials.gov (NCT05105087). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.